Esketamine is the active pharmaceutical compound in Spravato — one of the two mirror-image molecules that together make up ketamine, which underwent isolated study and clinical development for nearly a decade before reaching FDA approval. The drug received FDA clearance in 2019 for adults with treatment-resistant depression and additional approval in 2020 for adults whose major depressive disorder includes acute suicidal ideation. A subsequent expansion in 2025 approved the medication as standalone monotherapy for treatment-resistant depression, meaning patients are no longer required to be on a daily oral antidepressant alongside Spravato for the treatment to be prescribed. No other ketamine therapy holds an FDA approval. No other ketamine therapy is routinely reimbursed by Medicare, Medicaid managed care plans, or major commercial insurance carriers as standard practice.

During each session, the patient self-administers the nasal spray under direct supervision and remains in the treatment suite for at least two hours of clinical monitoring. The medication acts on glutamate signaling through NMDA receptor antagonism, producing the rapid response timeline that distinguishes Spravato from serotonin-based antidepressants. A clinical dosing analysis of esketamine published in Acta Psychiatrica Scandinavica examined how dosing decisions affect clinical response across patient populations. Behavioral health services in NJ operate within the framework of the New Jersey Division of Mental Health and Addiction Services. The fully coordinated clinical model behind our Spravato therapy in Manhattan integrates prescriber and psychotherapist care from intake through maintenance.

• Spravato is the only FDA-approved esketamine product on the United States market and is reimbursed by the majority of commercial and government insurance plans operating across New York.
• The glutamatergic mechanism places Spravato outside the entire serotonin-based antidepressant family, which is precisely what accounts for both the speed and the depth of clinical response patients experience.
• Spravato administration in New York operates under federal REMS protocols and falls within the regulatory framework set by the U.S. Drug Enforcement Administration’s controlled substance scheduling and oversight, which classifies and regulates the dispensing of esketamine as a Schedule III substance nationwide.

The geographic story for Fort Lee patients is unusually favorable. Local NJ Transit buses run to GWB Bus Station and Port Authority frequently throughout the day, and ride-share across the George Washington Bridge is typically a 15 to 20 minute trip outside rush-hour windows. For patients evaluating Spravato Treatment in Fort Lee NJ, the meaningful difference between providers usually comes down to clinical model rather than commute logistics. Here’s what tends to keep Fort Lee patients here once they walk through the door.

The FDA-approved indications for Spravato cover two adult clinical populations:

• Treatment-Resistant Depression (TRD): adults whose current depressive episode hasn’t adequately responded to at least two prior antidepressant medications taken at adequate dose and duration
• Major Depressive Disorder with Acute Suicidal Ideation or Behavior: adults with current MDD whose clinical presentation includes active suicidality

Fort Lee patients arriving at our intake typically come carrying extensive treatment histories — multiple SSRIs and SNRIs tried sequentially over years, often augmentation strategies with lithium, lamotrigine, or atypical antipsychotics, frequently long psychotherapy relationships that produced partial benefit without sustained remission. The Best Spravato Treatment clinic in Fort Lee area residents can practically access is one that takes that history as substantive clinical information rather than as a checklist of failed prior trials. Intake includes both medical and psychotherapeutic evaluation specifically designed to surface that trajectory and let it inform what comes next clinically.

The medication produces therapeutic effect through several mechanisms operating in coordination:

Patients arrive at Spravato® on widely different terms, and our three pathways exist to match that range without flattening it into a single workflow. The right format gets identified collaboratively during your initial consultation, based on symptom severity, your existing therapeutic relationships, and the depth of clinical work you want to engage in.

Care at our practice moves through several distinct stages, each playing a defined clinical role:

Environment matters during a Spravato session in ways most medical contexts underestimate. Our Manhattan facility was designed specifically for this kind of work — purpose-built around the requirements of dosing and recovery, rather than retrofitted from a different medical use case.

Practically that means lighting closer to a residential environment than an exam room, walls treated to absorb rather than reflect ambient noise, furniture comfortable enough for the two-hour observation window, optional ambient audio, sensory aids available on request. The physical flow moves the patient from arrival to dosing to recovery continuously, without the institutional choreography that defines most medical facilities.

Our clinic is located at 137 East 25th Street, 11th Floor, reached from Fort Lee via NJ Transit’s 158, 178, 181, or 188 bus to the GWB Bus Station with subway connection downtown to 28th Street, or via ride-share across the George Washington Bridge.

Financial logistics shouldn’t be the reason a Fort Lee patient who would benefit from Spravato doesn’t access it. Here’s how the picture works for the Spravato Treatment clinic in Fort Lee residents are considering in Manhattan:

Choosing whether to begin Spravato is meaningful clinical territory — not a transaction. The first step is a no-cost discovery call with our intake team where you walk through your specific situation, ask the questions actually on your mind, and get a clear picture of what treatment with us would look like. Some Fort Lee patients book their first intake within days of that initial call. Others take weeks or months to consider it before circling back. Both are reasonable. When the timing is right for you, we’re here.